Biocorrx Inc Financials
This page shows Biocorrx Inc (BICX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioCorRx’s dominant business mechanic is externally funded development spending, with operating needs still far ahead of modest customer revenue.
FY2025 operating cash outflow of-$2.3M was almost fully offset by financing inflow of$2.35M . Because the same pairing of external funding and cash burn appeared in the prior two years, the FY2025 revenue rebound did not yet change the company’s basic funding model.
This still carries a development-stage cost structure: R&D spending was
The balance sheet remains liquidity-constrained, with cash of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Biocorrx Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Biocorrx Inc has an operating margin of -606.0%, meaning the company retains $-606 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Biocorrx Inc's revenue surged 10301.1% year-over-year to $797K, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Biocorrx Inc has a moderate D/E ratio of -1.22. This balance of debt and equity financing earns a leverage score of 51/100.
Biocorrx Inc's current ratio of 0.10 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Biocorrx Inc passes 3 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Biocorrx Inc generates $0.67 in operating cash flow (-$2.3M OCF vs -$3.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Biocorrx Inc earns $-21.6 in operating income for every $1 of interest expense (-$4.8M vs $224K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Biocorrx Inc generated $797K in revenue in fiscal year 2025. This represents an increase of 10301.1% from the prior year.
Biocorrx Inc's EBITDA was -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Biocorrx Inc reported -$3.4M in net income in fiscal year 2025.
Biocorrx Inc earned $-0.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.2% from the prior year.
Cash & Balance Sheet
Biocorrx Inc held $139K in cash against $0 in long-term debt as of fiscal year 2025.
Biocorrx Inc had 24M shares outstanding in fiscal year 2025. This represents an increase of 84.1% from the prior year.
Margins & Returns
Biocorrx Inc's operating margin was -606.0% in fiscal year 2025, reflecting core business profitability.
Biocorrx Inc's net profit margin was -431.5% in fiscal year 2025, showing the share of revenue converted to profit.
Capital Allocation
Biocorrx Inc invested $1.8M in research and development in fiscal year 2025. This represents an increase of 19.3% from the prior year.
BICX Income Statement
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $215K | N/A | $635K+256.4% | $178K+32.1% | $135K | N/A | $0-100.0% | $4K |
| Cost of Revenue | $25K | N/A | N/A | N/A | $0 | N/A | $0 | $0 |
| Gross Profit | $189K | N/A | N/A | N/A | $135K | N/A | $0-100.0% | $4K |
| R&D Expenses | $352K | N/A | $1.0M+238.4% | $297K+83.3% | $162K | N/A | $460K-14.2% | $536K |
| SG&A Expenses | $775K | N/A | $1.1M-6.4% | $1.2M+38.1% | $886K | N/A | $1.2M+43.7% | $830K |
| Operating Income | -$956K | N/A | -$1.9M-37.6% | -$1.4M-50.7% | -$938K | N/A | -$1.7M-21.2% | -$1.4M |
| Interest Expense | $12K | N/A | $30K-19.1% | $37K-58.1% | $87K | N/A | $149K-53.1% | $318K |
| Income Tax | N/A | N/A | N/A | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$831K | N/A | -$1.9M-55.5% | -$1.2M-46.6% | -$841K | N/A | -$1.5M-22.2% | -$1.2M |
| EPS (Diluted) | $-0.03 | N/A | $-0.11-57.1% | $-0.07 | N/A | N/A | $-0.14-7.7% | $-0.13 |
BICX Balance Sheet
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3M+8.3% | $2.1M-71.5% | $7.5M+12.8% | $6.7M-1.8% | $6.8M+1662.2% | $386K-40.0% | $644K+34.5% | $479K |
| Current Assets | $1.0M+25.3% | $814K-44.3% | $1.5M+177.2% | $527K-6.8% | $566K+379.5% | $118K-66.6% | $353K+105.3% | $172K |
| Cash & Equivalents | $212K+52.1% | $139K-51.6% | $288K+157.2% | $112K+363.4% | $24K-72.6% | $88K+97714.4% | $90-98.9% | $8K |
| Inventory | $143K0.0% | $143K-7.7% | $155K+16.3% | $134K0.0% | $134K | $0 | N/A | N/A |
| Accounts Receivable | $330K+30.3% | $253K+30.4% | $194K+279.5% | $51K-54.2% | $112K | $0 | $0 | $0 |
| Goodwill | $563K0.0% | $563K-80.2% | $2.8M0.0% | $2.8M0.0% | $2.8M | $0 | N/A | N/A |
| Total Liabilities | $13.9M+2.0% | $13.7M-32.6% | $20.3M+3.1% | $19.7M+5.9% | $18.6M+48.7% | $12.5M+0.3% | $12.5M+8.7% | $11.5M |
| Current Liabilities | $8.5M+2.7% | $8.3M-44.8% | $15.0M+3.3% | $14.6M+8.3% | $13.4M+63.8% | $8.2M-0.2% | $8.2M+12.4% | $7.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$11.5M-2.0% | -$11.2M+16.8% | -$13.5M-6.8% | -$12.6M-9.2% | -$11.6M+4.7% | -$12.1M-2.4% | -$11.8M-7.5% | -$11.0M |
| Retained Earnings | -$87.5M-1.0% | -$86.6M+0.6% | -$87.2M-2.2% | -$85.3M-1.5% | -$84.1M-1.0% | -$83.2M-1.4% | -$82.0M-1.8% | -$80.6M |
BICX Cash Flow Statement
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$433K+48.9% | -$848K-33.6% | -$634K-401.5% | -$126K+81.7% | -$690K-179.0% | -$247K+30.9% | -$358K-135.4% | -$152K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $506K-27.7% | $699K-13.7% | $810K+278.2% | $214K-65.8% | $626K+86.7% | $335K-4.1% | $349K+490.4% | $59K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BICX Financial Ratios
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3% | N/A | N/A | N/A | 100.0% | N/A | N/A | 100.0% |
| Operating Margin | -445.6% | N/A | -306.3%+487.0pp | -793.3%-98.0pp | -695.3% | N/A | N/A | -33852.9% |
| Net Margin | -387.4% | N/A | -301.9%+390.1pp | -692.0%-68.3pp | -623.7% | N/A | N/A | -30095.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -35.8% | N/A | -25.5%-7.0pp | -18.5%-6.1pp | -12.4% | N/A | -231.1%+23.3pp | -254.4% |
| Current Ratio | 0.12+0.0 | 0.100.0 | 0.10+0.1 | 0.040.0 | 0.04+0.0 | 0.01-0.0 | 0.04+0.0 | 0.02 |
| Debt-to-Equity | -1.220.0 | -1.22+0.3 | -1.51+0.1 | -1.56+0.0 | -1.61-0.6 | -1.03+0.0 | -1.05-0.0 | -1.04 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$11.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Biocorrx Inc's annual revenue?
Biocorrx Inc (BICX) reported $797K in total revenue for fiscal year 2025. This represents a 10301.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biocorrx Inc's revenue growing?
Biocorrx Inc (BICX) revenue grew by 10301.1% year-over-year, from $8K to $797K in fiscal year 2025.
Is Biocorrx Inc profitable?
No, Biocorrx Inc (BICX) reported a net income of -$3.4M in fiscal year 2025, with a net profit margin of -431.5%.
What is Biocorrx Inc's EBITDA?
Biocorrx Inc (BICX) had EBITDA of -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biocorrx Inc's operating margin?
Biocorrx Inc (BICX) had an operating margin of -606.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biocorrx Inc's net profit margin?
Biocorrx Inc (BICX) had a net profit margin of -431.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biocorrx Inc's operating cash flow?
Biocorrx Inc (BICX) generated -$2.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biocorrx Inc's total assets?
Biocorrx Inc (BICX) had $2.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Biocorrx Inc spend on research and development?
Biocorrx Inc (BICX) invested $1.8M in research and development during fiscal year 2025.
What is Biocorrx Inc's current ratio?
Biocorrx Inc (BICX) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Biocorrx Inc's debt-to-equity ratio?
Biocorrx Inc (BICX) had a debt-to-equity ratio of -1.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biocorrx Inc's return on assets (ROA)?
Biocorrx Inc (BICX) had a return on assets of -160.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biocorrx Inc's cash runway?
Based on fiscal year 2025 data, Biocorrx Inc (BICX) had $139K in cash against an annual operating cash burn of $2.3M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Biocorrx Inc's debt-to-equity ratio negative or unusual?
Biocorrx Inc (BICX) has negative shareholder equity of -$11.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Biocorrx Inc's Piotroski F-Score?
Biocorrx Inc (BICX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biocorrx Inc's earnings high quality?
Biocorrx Inc (BICX) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biocorrx Inc cover its interest payments?
Biocorrx Inc (BICX) has an interest coverage ratio of -21.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biocorrx Inc?
Biocorrx Inc (BICX) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.